Background The objectives of this study were to evaluate the safety profile of aflibercept and
health-related quality of life (HRQL) in patients with metastatic colorectal cancer (mCRC) …

Abstract Background FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin)+ aflibercept
improves median overall survival (OS) and progression-free survival (PFS) in patients with …

Simple Summary The continuum of care for mCRC might include anti-angiogenic drug as
anti-VEGF/VEGFR moAb and recombinant proteins in combination with fluoropyrimidine …

Background The Ph 3 VELOUR study demonstrated that addition of aflibercept (ziv-
aflibercept [USA]) to fixed-dose FOLFIRI improved survival outcomes & response rates in …

Objective: Aflibercept increased overall survival with acceptable tolerability in metastatic
colorectal cancer (mCRC) when it was used in combination with FOLFIRI after progression …

Purpose In the VELOUR study, aflibercept+ FOLFIRI regimen resulted in improved survival
in metastatic colorectal cancer (mCRC) patients who progressed after oxaliplatin. The use of …

Simple Summary Colorectal cancer (CRC) is the third most frequently diagnosed
malignancy worldwide and the second leading cause of cancer-related mortality. In …

Aflibercept is a recombinant fusion protein that acts as a soluble decoy receptor for vascular
endothelial growth factor (VEGF), a key regulator of angiogenesis. It binds to all isoforms of …

Aflibercept targets vascular endothelial growth factor. The present study involved assessing
the efficacy, safety and pharmacokinetics of aflibercept plus 5‐fluorouracil/levofolinate …

Background Aflibercept combined with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) as
second-line treatment of metastatic colorectal cancer (mCRC) significantly improved survival …